Drug Approval | May 03, 2025
USFDA inspection at Concord Biotech’s API facility at Dholka
These observations are procedural in nature and none of them are related to data integrity
These observations are procedural in nature and none of them are related to data integrity
The inspection was successfully completed
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
Eris Lifesciences enters into term loan agreement with Citi Bank
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
ANVISA issues CGMP to Concord Biotech’s Unit I
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Subscribe To Our Newsletter & Stay Updated
